<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00986999</url>
  </required_header>
  <id_info>
    <org_study_id>H002</org_study_id>
    <secondary_id>R01HL095135</secondary_id>
    <nct_id>NCT00986999</nct_id>
  </id_info>
  <brief_title>Effect of Rosuvastatin on Endothelial Function</brief_title>
  <official_title>Pilot Study of the Effect of Low-Dose Rosuvastatin on Endothelial Function, Oxidative Stress and Inflammatory Parameters in HIV-Infected Individuals With Low HDL Cholesterol Levels and Low to Normal LDL Cholesterol Levels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Hawaii</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Hawaii</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rosuvastatin belongs to a class of medications commonly called &quot;statins&quot; which are
      medications given for high low density lipoprotein (LDL) 'bad' cholesterol to prevent
      atherosclerosis (hardening of blood vessels) and lower risk of heart attacks and other
      circulation problems. Recent studies in the general non-HIV infected population have shown
      that the beneficial effect of statins in preventing circulation problems is larger than would
      be expected from lowering of LDL-cholesterol alone. It has been suggested that the additional
      beneficial effect of statins may be due to the anti-inflammatory effect of statins.

      The risk of heart attacks and other circulation problems may be high in HIV infected
      individuals. This may be due to the inflammatory stress effects of HIV. The main purpose of
      the study is to see if rosuvastatin will have a beneficial effect on the circulatory system
      in HIV infected individuals even in those who do not have high LDL cholesterol levels.
      Therefore, in HIV-infected individuals with normal or low LDL cholesterol levels but with
      evidence of low HDL cholesterol levels which may be a sign of low grade inflammation, the
      study will look at whether 3 months of rosuvastatin will lead to improvement in brachial
      artery flow-mediated dilatation (FMD), a marker of early atherosclerosis (hardening of the
      blood vessels).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    poor enrollment
  </why_stopped>
  <start_date>September 2009</start_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Flow Mediated Dilatation (FMD) of the Brachial Artery</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in HIV Biomarkers of Immune Activation to Include CD38 and CD69 Expression on T Cells and CD16 and CD69 Expression on Monocytes</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mitochondrial-specific Oxidative Stress (Mt-specific 8-oxo-dG) and Oxidative Phosphorylation (OXPHOS) Protein/Enzyme Activity [Complex I and Complex IV] Levels</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Glucose Homeostasis and Insulin Resistance as Assessed by Oral Glucose Tolerance Testing</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total, HDL and LDL Cholesterol and Triglyceride Levels</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hsCRP</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>HIV Infections</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>rosuvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rosuvastatin 10 mg qd increased to 20 mg qd as tolerated</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rosuvastatin</intervention_name>
    <description>rosuvastatin 20 mg tablet, 1/2 tab qd increased to a full tablet qd as tolerated x 6 months with optional extension to 2 years</description>
    <arm_group_label>rosuvastatin</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV infection

          -  Age &gt; 18 years old

          -  On stable antiretroviral therapy for &gt; 6 months with no plans to change therapy during
             the treatment phase of the study

          -  Plasma HIV RNA &lt; 50 copies/mL

          -  Karnofsky performance score &gt; 70 within 30 days prior to study entry

          -  Ability to understand and sign informed consent

          -  Following laboratory values obtained within 30 days prior to randomization:

               -  Absolute neutrophil count (ANC) &gt; 750/mm3

               -  Hemoglobin &gt;/= 8.0 g/dL

               -  Platelets &gt;/= 50,000/mm3

               -  ALT (SGPT) and AST (SGOT) &lt; 2.5 x ULN

               -  Fasting glucose &lt; 126 mg/dL

               -  TSH &lt; 3.0 mIU/L

          -  HDL-C &lt; 50 mg/dL in men, &lt; 55 mg/dL in women

          -  Direct LDL-C &lt;/= 130 mg/dL

          -  Calculated creatinine clearance &gt; 50 mL/min

          -  Willing to be treated with rosuvastatin or be on an observational arm for a minimum of
             3 months

          -  Female subject must not participate in a conception process (active attempt to become
             pregnant) or be post-menopausal. If participating in sexual activity that could lead
             to pregnancy, the subject must use contraception while receiving study medication and
             30 days after stopping the medication

        Exclusion criteria

          -  History of past cardiovascular event

          -  Acute illnesses or active AIDS-defining opportunistic infection (OI) within 30 days
             prior to entry

          -  Other chronic illness including diabetes, autoimmune diseases, and endocrinopathies

          -  Serology positive for hepatitis B surface antigen or hepatitis C antibody

          -  Signs and symptoms of liver failure

          -  Receipt of supraphysiologic glucocorticoid therapy within 3 months prior to study
             entry

          -  Use of lipid lowering agents within 30 days prior to study entry

          -  Receipt of an HIV vaccine or investigational agents

          -  Pregnancy or breast-feeding

          -  Presence of any active malignancy within the last 5 years

          -  Severe Hypertension (Systolic &gt;/= 180 or Diastolic &gt;/= 110 mm Hg)

          -  Use of oral postmenopausal hormone replacement therapy

          -  Known hypersensitivity to rosuvastatin

          -  Active drug or alcohol dependence

          -  Any acute illness within 30 days prior to study entry that, in the opinion of the site
             investigator, would interfere with participation in the study.

          -  Use of lopinavir/ritonavir (Kaletra) as part of current HIV antiretroviral regimen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cecilia Shikuma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hawaii Center for AIDS, John A. Burns School of Medicine, University of Hawaii</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hawaii Center for AIDS</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2009</study_first_submitted>
  <study_first_submitted_qc>September 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2009</study_first_posted>
  <results_first_submitted>January 20, 2015</results_first_submitted>
  <results_first_submitted_qc>January 20, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 29, 2015</results_first_posted>
  <last_update_submitted>January 20, 2015</last_update_submitted>
  <last_update_submitted_qc>January 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV infected</keyword>
  <keyword>treatment experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Rosuvastatin</title>
          <description>rosuvastatin 10 mg qd increased to 20 mg qd as tolerated
rosuvastatin: rosuvastatin 20 mg tablet, 1/2 tab qd increased to a full tablet qd as tolerated x 6 months with optional extension to 2 years</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rosuvastatin</title>
          <description>rosuvastatin 10 mg qd increased to 20 mg qd as tolerated
rosuvastatin: rosuvastatin 20 mg tablet, 1/2 tab qd increased to a full tablet qd as tolerated x 6 months with optional extension to 2 years</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Flow Mediated Dilatation (FMD) of the Brachial Artery</title>
        <time_frame>3 months</time_frame>
        <population>Not analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>rosuvastatin 10 mg qd increased to 20 mg qd as tolerated
rosuvastatin: rosuvastatin 20 mg tablet, 1/2 tab qd increased to a full tablet qd as tolerated x 6 months with optional extension to 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Flow Mediated Dilatation (FMD) of the Brachial Artery</title>
          <population>Not analyzed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HIV Biomarkers of Immune Activation to Include CD38 and CD69 Expression on T Cells and CD16 and CD69 Expression on Monocytes</title>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>rosuvastatin 10 mg qd increased to 20 mg qd as tolerated
rosuvastatin: rosuvastatin 20 mg tablet, 1/2 tab qd increased to a full tablet qd as tolerated x 6 months with optional extension to 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HIV Biomarkers of Immune Activation to Include CD38 and CD69 Expression on T Cells and CD16 and CD69 Expression on Monocytes</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mitochondrial-specific Oxidative Stress (Mt-specific 8-oxo-dG) and Oxidative Phosphorylation (OXPHOS) Protein/Enzyme Activity [Complex I and Complex IV] Levels</title>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>rosuvastatin 10 mg qd increased to 20 mg qd as tolerated
rosuvastatin: rosuvastatin 20 mg tablet, 1/2 tab qd increased to a full tablet qd as tolerated x 6 months with optional extension to 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mitochondrial-specific Oxidative Stress (Mt-specific 8-oxo-dG) and Oxidative Phosphorylation (OXPHOS) Protein/Enzyme Activity [Complex I and Complex IV] Levels</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Glucose Homeostasis and Insulin Resistance as Assessed by Oral Glucose Tolerance Testing</title>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>rosuvastatin 10 mg qd increased to 20 mg qd as tolerated
rosuvastatin: rosuvastatin 20 mg tablet, 1/2 tab qd increased to a full tablet qd as tolerated x 6 months with optional extension to 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Glucose Homeostasis and Insulin Resistance as Assessed by Oral Glucose Tolerance Testing</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total, HDL and LDL Cholesterol and Triglyceride Levels</title>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>rosuvastatin 10 mg qd increased to 20 mg qd as tolerated
rosuvastatin: rosuvastatin 20 mg tablet, 1/2 tab qd increased to a full tablet qd as tolerated x 6 months with optional extension to 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total, HDL and LDL Cholesterol and Triglyceride Levels</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in hsCRP</title>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>rosuvastatin 10 mg qd increased to 20 mg qd as tolerated
rosuvastatin: rosuvastatin 20 mg tablet, 1/2 tab qd increased to a full tablet qd as tolerated x 6 months with optional extension to 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change in hsCRP</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Rosuvastatin</title>
          <description>rosuvastatin 10 mg qd increased to 20 mg qd as tolerated
rosuvastatin: rosuvastatin 20 mg tablet, 1/2 tab qd increased to a full tablet qd as tolerated x 6 months with optional extension to 2 years</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Cecilia M. Shikuma M.D.</name_or_title>
      <organization>University of Hawaii</organization>
      <phone>808 692-1328</phone>
      <email>shikuma@hawaii.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

